Merck is already in phase 3 testing for its next-generation pneumococcal vaccine, and Pfizer's CFO said his company is "all in" on advancing its…

AstraZeneca’s latest data on its triple-combination COPD candidate may not do much to help it against rival GlaxoSmithKline.

The new eczema data came a month ahead of an expected FDA decision on the drug's fate in asthma.

Sticker prices in drug ads might be off the table again, thanks to some in the U.S. House of Representatives.

Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.

There's a dearth of treatments for early-stage lung cancer, so J&J is raising a flag in the field to hunt for sparks of innovation.

GSK listened to social media to create Excedrin ad images headache sufferers relate to—plus clever custom boxes tagged with pain triggers.

Pfizer and Merck KGaA are one step closer to a brand-new market for their latecomer immuno-oncology drug Bavencio.